News of cure ‘monumental’ for cystic fibrosis sufferers: Iowa CFF chapter presiden PDF Print E-mail
News Releases - Health, Medicine & Nutrition
Written by Mark Perlman   
Friday, 27 June 2014 14:16

Mygooi CEO Greenwood lauds local, national support

DES MOINES, Iowa (June 26, 2014) News that Phase 3 clinical studies of a combination of two medications have been successful for patients with the most common form of cystic fibrosis is wonderful, says Paul N. Greenwood, president of the Iowa chapter of the Cystic Fibrosis Foundation and CEO of Des Moines-based

The results of two 24-week studies held at 200 sites in North America, Europe and Australia, were announced Tuesday ( by Vertex Pharmaceuticals Inc., which developed the drugs and protocol with the support of the Cystic Fibrosis Foundation.

“This is monumental news,” said Greenwood, “the most exciting in CF history. I have to thank the people of Iowa, who contributed millions of dollars to this cause in the 10 years I’ve been volunteering with our chapter. This is a terrible disease and, while there’s still a lot of work to be done, this is a massive step forward.”

Vertex and CFF said the studies ple with two copies of the F508del mutation.

These results represent an important milestone for the CF Community. The knowledge gained from these studies provides an important building block in our efforts to target the root case of the disease in ALL People with CF!showed significant improvements for people with two copies of the F508del mutation, about half of all CF cases. Vertex is looking for possible FDA approval of the treatment in 2015. Robert J. Beall, Ph.D., national president and CEO of CFF, said the studies “validate that we are on the right road to getting new and effective treatments into the hands of people who so desperately need them.”

More than 1,100 people ages 12 and older participated in the studies. Those given the treatment showed significant and consistent improvement in lung function and other important health measures for CF, including weight gain and a reduction in the rate of pulmonary exacerbations and related hospitalizations and IV antibiotic use.

About Mygooi

Mygooi™ ( is an energetic brand platform that is digital, creative, disruptive and global. Its portfolio of emerging products sizzle with IC/DC (Innovation and Creativity/Disruption and Community). Mygooi’s utility and purpose are to bring people together with innovative digital products. Based in Des Moines, Iowa, and Chennai, India, Mygooi has as its mission to Go Where The Life Is.™

Mygooi supports the Cystic Fibrosis Foundation. Check them out at

blog comments powered by Disqus

Comments (0)Add Comment

Write comment
You must be logged in to post a comment. Please register if you do not have an account yet.